BENJAMIN F. EDWARDS & COMPANY, INC. - CATABASIS PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
BENJAMIN F. EDWARDS & COMPANY, INC. ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$4,000
-33.3%
2,0000.0%0.00%
Q1 2021$6,000
+50.0%
2,0000.0%0.00%
Q4 2020$4,000
-66.7%
2,0000.0%0.00%
-100.0%
Q3 2020$12,000
-7.7%
2,0000.0%0.00%0.0%
Q2 2020$13,000
+62.5%
2,0000.0%0.00%0.0%
Q1 2020$8,000
-33.3%
2,0000.0%0.00%0.0%
Q4 2019$12,000
+9.1%
2,0000.0%0.00%0.0%
Q3 2019$11,000
-31.2%
2,0000.0%0.00%0.0%
Q2 2019$16,0000.0%2,0000.0%0.00%0.0%
Q1 2019$16,000
+77.8%
2,0000.0%0.00%0.0%
Q4 2018$9,0002,0000.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders